Evidence map›Paper›PMID 40665788›Full record

ArticleInternational journal of cancer2025

Rapid COJEC without myeloablative therapy for high-risk neuroblastoma.

Brian H Kushner, Ellen M Basu, Fiorella Iglesias Cardenas, Kim Kramer, Shakeel Modak

Abstract read
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Brian H KushnerDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-8916-0697
Ellen M BasuDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Fiorella Iglesias CardenasDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kim KramerDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Shakeel ModakDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-7280-1726

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Arnold J. Jacobs Pediatric Cancer FundBand of Parents FoundationKatie's Find A Cure FundNCI NIH HHS P30 CA008748Rhyan Loos Family FundRobert Steel Foundation
6 · The paper itself

Abstract

Myeloablative therapy (MAT) is included in high-risk neuroblastoma (HR-NB) treatment programs of the Children's Oncology Group (COG) and the Societe Internationale d'Oncologie Pediatrique Europe Neuroblastoma (SIOPEN), but not at Memorial Sloan Kettering Cancer Center (MSK). COG and SIOPEN programs achieved 3-5-year event-free survival rates of ~50%-60%, similar to the MSK experience without MAT which involved patients treated with COG or MSK induction and anti-G

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeuroblastomaAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedChildChild, PreschoolFemaleGranulocyte-Macrophage Colony-Stimulating FactorHumansImmunoglobulin GInfantMaleRetrospective Studies3F8 antibodyAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedGranulocyte-Macrophage Colony-Stimulating FactorImmunoglobulin GCOJECimmunotherapyneuroblastoma

Identifiers

PMID40665788
PMCPMC13436022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.